To B-(RAF) or Not to Be

被引：0

作者：

Dummer, Reinhard ^{[1
]}

Goldinger, Simone M. ^{[1
]}

Widmer, Daniel ^{[1
]}

Dreier, Jil ^{[1
]}

Levesque, Mitchell P. ^{[1
]}

机构：

[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland

来源：

JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2014年 / 134卷 / 05期

关键词：

METASTATIC MELANOMA; IMPROVED SURVIVAL; OPEN-LABEL; RESISTANCE; HETEROGENEITY; SELUMETINIB; VEMURAFENIB; MUTATION; THERAPY; PHASE-2;

D O I：

10.1038/jid.2014.62

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The identification of targetable mutations has revolutionized the therapy of metastatic melanoma. In particular, BRAF and MEK inhibitors have a well-documented impact on overall survival in metastatic disease. However, therapeutic success is highly dependent on the correct identification of these mutations. We discuss the impact of molecular heterogeneity in this context.

引用

页码：1200 / 1201

页数：2

共 15 条

[1] MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].

Ascierto, Paolo A. ;

Schadendorf, Dirk ;

Berking, Carola ;

Agarwala, Sanjiv S. ;

van Herpen, Carla M. L. ;

Queirolo, Paola ;

Blank, Christian U. ;

Hauschild, Axel ;

Beck, J. Thaddeus ;

St-Pierre, Annie ;

Niazi, Faiz ;

Wandel, Simon ;

Peters, Malte ;

Zubel, Angela ;

Dummer, Reinhard .

LANCET ONCOLOGY, 2013, 14 (03) :249-256

[2] T-helper-1-cell cytokines drive cancer into senescence [J].

Braumueller, Heidi ;

Wieder, Thomas ;

Brenner, Ellen ;

Assmann, Sonja ;

Hahn, Matthias ;

Alkhaled, Mohammed ;

Schilbach, Karin ;

Essmann, Frank ;

Kneilling, Manfred ;

Griessinger, Christoph ;

Ranta, Felicia ;

Ullrich, Susanne ;

Mocikat, Ralph ;

Braungart, Kilian ;

Mehra, Tarun ;

Fehrenbacher, Birgit ;

Berdel, Julia ;

Niessner, Heike ;

Meier, Friedegund ;

van den Broek, Maries ;

Haering, Hans-Ulrich ;

Handgretinger, Rupert ;

Quintanilla-Martinez, Leticia ;

Fend, Falko ;

Pesic, Marina ;

Bauer, Juergen ;

Zender, Lars ;

Schaller, Martin ;

Schulze-Osthoff, Klaus ;

Roecken, Martin .

NATURE, 2013, 494 (7437) :361-365

[3] Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[4] Human CD271-Positive Melanoma Stem Cells Associated with Metastasis Establish Tumor Heterogeneity and Long-term Growth [J].

Civenni, Gianluca ;

Walter, Anne ;

Kobert, Nikita ;

Mihic-Probst, Daniela ;

Zipser, Marie ;

Belloni, Benedetta ;

Seifert, Burkhardt ;

Moch, Holger ;

Dummer, Reinhard ;

van den Broek, Maries ;

Sommer, Lukas .

CANCER RESEARCH, 2011, 71 (08) :3098-3109

[5] Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights [J].

Dummer, Reinhard ;

Flaherty, Keith T. .

CURRENT OPINION IN ONCOLOGY, 2012, 24 (02) :150-154

[6] Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma [J].

Flaherty, Keith T. ;

Robert, Caroline ;

Hersey, Peter ;

Nathan, Paul ;

Garbe, Claus ;

Milhem, Mohammed ;

Demidov, Lev V. ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

Mohr, Peter ;

Dummer, Reinhard ;

Trefzer, Uwe ;

Larkin, James M. G. ;

Utikal, Jochen ;

Dreno, Brigitte ;

Nyakas, Marta ;

Middleton, Mark R. ;

Becker, Juergen C. ;

Casey, Michelle ;

Sherman, Laurie J. ;

Wu, Frank S. ;

Ouellet, Daniele ;

Martin, Anne-Marie ;

Patel, Kiran ;

Schadendorf, Dirk .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (02) :107-114

[7] In vivo switching of human melanoma cells between proliferative and invasive states [J].

Hoek, Keith S. ;

Eichhoff, Ossia M. ;

Schlegel, Natalie C. ;

Doebbeling, Udo ;

Kobert, Nikita ;

Schaerer, Leo ;

Hemmi, Silvio ;

Dummer, Reinhard .

CANCER RESEARCH, 2008, 68 (03) :650-656

[8] Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? [J].

Hoelzel, Michael ;

Bovier, Anton ;

Tueting, Thomas .

NATURE REVIEWS CANCER, 2013, 13 (05) :365-U95

[9] Phase II, Open-Label, Randomized Trial of the MEK1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma [J].

Kirkwood, John M. ;

Bastholt, Lars ;

Robert, Caroline ;

Sosman, Jeff ;

Larkin, James ;

Hersey, Peter ;

Middleton, Mark ;

Cantarini, Mireille ;

Zazulina, Victoria ;

Kemsley, Karin ;

Dummer, Reinhard .

CLINICAL CANCER RESEARCH, 2012, 18 (02) :555-567

[10] Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation [J].

Landsberg, Jennifer ;

Kohlmeyer, Judith ;

Renn, Marcel ;

Bald, Tobias ;

Rogava, Meri ;

Cron, Mira ;

Fatho, Martina ;

Lennerz, Volker ;

Woelfel, Thomas ;

Hoelzel, Michael ;

Tueting, Thomas .

NATURE, 2012, 490 (7420) :412-+

← 1 2 →